secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2021-07-30T23:59:59+00:00
Accession:  0001104659-21-097921
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iRadimed Q2 2021 revenue $9.8M, GAAP EPS $0.12; guides FY21 rev $40.0-40.4M
---------------------------------------------------------------------------

- Q2 2021 revenue $9.8M, up 44% YoY from $6.8M; net income $1.5M vs net loss of $2.1M.
- GAAP diluted EPS $0.12; non-GAAP diluted EPS $0.14, up from $0.05 in Q2 2020.
- Q3 2021 guidance: rev $10.3-10.5M, GAAP EPS $0.14-0.15, non-GAAP EPS $0.16-0.17.
- Full-year 2021 guidance: rev $40.0-40.4M, GAAP EPS $0.53-0.55, non-GAAP EPS $0.60-0.62.
- Cash and investments $56.1M at quarter-end; operating cash flow $4.5M YTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000110465921097921/0001104659-21-097921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000110465921097921/tm2123649d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-097921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer